Effect of Vitamin D Supplementation in Prostate Cancer: A Systematic Review of Randomized Control Trials.
Int J Vitam Nutr Res. 2019 Apr 30:1-13. doi: 10.1024/0300-9831/a000494.
Petrou S1, Mamais I2, Lavranos G3, Tzanetakou IP1, Chrysostomou S1.
- Overview Prostate Cancer and Vitamin D
- Prostate and Urinary systems much better with higher vitamin D – many studies
- Prostate surgery outcomes vary with Vitamin D Receptors– May 2017
- Prostate Cancer might be treated by 4,000 IU of vitamin D and aspirin – RCT 2021
- The risk of 40 diseases at least double with poor Vitamin D Receptor as of July 2019
- Calcitriol category listing has
56 items along with related searches The Meta-analysis of Prostate Cancer
- 1.5X more likely to die of Prostate Cancer if low vitamin D when initially diagnosed – meta-analysis March 2024
- Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020
- Variety of Vitamin D forms treat Prostate Cancer – RCT Review April 2019
- Prostate Cancer death 40 percent less likely if 40 ng level of vitamin D – Meta-analysis Oct 2018
- Prostate cancer risk increase with Vitamin D (other studies disagree) – meta-analysis Jan 2018
- Meta-graphs of vitamin D and Cancer – Dec 2011
- Risk of Prostate Cancer weakly associated with vitamin D - meta-analysis March 2011
- 16 percent less Prostate Cancer sometimes for each 10 ng vitamin D increase - meta-analysis Jan 2011
- Meta-analysis found vitamin D association with colon but not prostate nor breast cancer May 2010
Prostate Cancer and Omega-3
- 2.5 X reduced risk of cancer in 70 year-olds by a small amount of Vitamin D, Omega-3 and exercise – RCT April 2022
- Prostate Cancer PSA reduced by 60 ng of Vitamin D, Vitamin B complex, Omega-3, Curcumin and diet – June 2021
- Men with High Omega-3 ratio 3 times less likely to have high grade prostate cancer – July 2019
- Low-Grade Prostate Cancer 70 percent less likely to progress if good level of Omega-3 – June 2018
- Prostate Cancer treatment (Vitamin D, Omega-3, Tumeric) RCT ending Dec 2018
Vitamin D is important in many cellular functions including cell cycling and proliferation, differentiation, and apoptosis. Via the induction of cell cycle arrest and/or apoptosis, vitamin D inhibits normal prostatic epithelial cells growth. Review the evidence of the effect of vitamin D supplementation on prostate cancer (PC) biomarkers and patient survival and assess optimal dosage, formulation and duration. Pubmed, Medline and Ebsco Host databases were systematically searched for relevant literature. 8 Randomized Controlled Trials were included in this review. All studies, besides one, were of high methodological quality.- 4 studies used calcitriol (0,5-45 pg/weekly),
- 2 studies have used vitamin D3 (150-1000 μg/daily) and
- 2 other studies have used 1α-hydroxy Vitamin D2 (10 μg/daily or weekly).
Duration of supplementation varied between 28 days up to 18.3 months.
- Two studies had positive effects on prostate specific antigen (PSA) (p < .05),
- 1 study had a significant positive effect on median survival (p < .05) and
- 1 study showed a significant reduction of vitamin D receptor (VDR) expression (p < .05).
The remaining studies showed negative or no effect on PC characteristics, clinical outcomes and/or survival. Current evidence suggests that vitamin D supplementation in conjunction with standard of care (e.g. chemotherapy, radiation therapy) may confer clinical benefits such as a decrease in serum PSA levels and VDR expression but further research is required to ascertain these results. Calcitriol supplementation in doses ranging from 250-1000 mg for 3-8 weeks or a lower dose of 45 mg for 18.3 months, appear most beneficial regarding outcomes of PC progression and survival.
Printer Friendly Follow this page for updates3921 visitors, last modified 12 Jul, 2019,